TSHA · CIK 0001806310
What Taysha Gene Therapies, Inc. told the SEC could break it.
1 self-disclosed vulnerability, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for TSHA. More may follow as additional filings are processed.
In its own words
What could break it.
Supplier concentration
- AAV9 starting-material dependence — all current and planned product candidates require AAV9 raw material, sometimes limited/sole-sourced; reliance on third-party contract manufacturers for AAV9 under heavy regulationmedium
Taysha's entire gene-therapy pipeline depends on a single critical starting material: every current and planned product candidate (TSHA-102 for Rett syndrome, TSHA-120 for GAN, etc.) requires AAV9 raw material, leaving it particularly susceptible to shortages, delays or an inability to obtain suitable AAV9. Some raw materials are limited- or sole-sourced, and a supply interruption could materially harm its ability to manufacture candidates until a new source is identified and qualified — which may not be possible in a reasonable time or on commercially reasonable terms. It also relies on third-party contract manufacturers for AAV9, who are subject to significant manufacturing regulation, so a CMO quality, capacity or compliance failure would delay clinical development or any commercialization. As a clinical-stage company with no approved products, such a disruption is existential. Suppliers/CMOs unnamed, so a sole-source risk rather than an edge. Severity high.
“We are particularly susceptible to any shortages, delays or our inability to obtain suitable AAV9 raw materials, given that all of our current and planned product candidates require this starting material.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Astellas Pharma Inc.
“the Securities Purchase Agreement (and together with the Option Agreement, the Astellas Transactions), with Astellas.”
Cited →“aysha relating to Taysha's development program for TSHA-118 for CLN1 disease.”
Cited →University of Texas Southwestern Medical Center
“UT Southwestern, which could slow down or hamper our ability to enforce our licensed intellectual property rights.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch